182 related articles for article (PubMed ID: 23374508)
21. Slc10a2-null mice uncover colon cancer-promoting actions of endogenous fecal bile acids.
Raufman JP; Dawson PA; Rao A; Drachenberg CB; Heath J; Shang AC; Hu S; Zhan M; Polli JE; Cheng K
Carcinogenesis; 2015 Oct; 36(10):1193-200. PubMed ID: 26210740
[TBL] [Abstract][Full Text] [Related]
22. Identification of a region of the ileal-type sodium/bile acid cotransporter interacting with a competitive bile acid transport inhibitor.
Hallén S; Björquist A; Ostlund-Lindqvist AM; Sachs G
Biochemistry; 2002 Dec; 41(50):14916-24. PubMed ID: 12475240
[TBL] [Abstract][Full Text] [Related]
23. Ileal apical sodium-dependent bile acid transporter protein levels are down-regulated through ubiquitin-dependent protein degradation induced by bile acids.
Miyata M; Yamakawa H; Hayashi K; Kuribayashi H; Yamazoe Y; Yoshinari K
Eur J Pharmacol; 2013 Aug; 714(1-3):507-14. PubMed ID: 23872411
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of intestinal bile acid transporter Slc10a2 improves triglyceride metabolism and normalizes elevated plasma glucose levels in mice.
Lundåsen T; Andersson EM; Snaith M; Lindmark H; Lundberg J; Östlund-Lindqvist AM; Angelin B; Rudling M
PLoS One; 2012; 7(5):e37787. PubMed ID: 22662222
[TBL] [Abstract][Full Text] [Related]
25. The cytosolic half of helix III forms the substrate exit route during permeation events of the sodium/bile acid cotransporter ASBT.
Hussainzada N; Claro Da Silva T; Swaan PW
Biochemistry; 2009 Sep; 48(36):8528-39. PubMed ID: 19653651
[TBL] [Abstract][Full Text] [Related]
26. SLC10A2 deficiency-induced congenital chronic bile acid diarrhea and stunting.
Qie D; Zhang Y; Gong X; He Y; Qiao L; Lu G; Li Y
Mol Genet Genomic Med; 2021 Aug; 9(8):e1740. PubMed ID: 34192422
[TBL] [Abstract][Full Text] [Related]
27. Putative irreversible inhibitors of the human sodium-dependent bile acid transporter (hASBT; SLC10A2) support the role of transmembrane domain 7 in substrate binding/translocation.
González PM; Hussainzada N; Swaan PW; Mackerell AD; Polli JE
Pharm Res; 2012 Jul; 29(7):1821-31. PubMed ID: 22354836
[TBL] [Abstract][Full Text] [Related]
28.
Ticho AL; Malhotra P; Manzella CR; Dudeja PK; Saksena S; Gill RK; Alrefai WA
J Biol Chem; 2020 Apr; 295(14):4488-4497. PubMed ID: 32071081
[TBL] [Abstract][Full Text] [Related]
29. Substrate specificity of the ileal and the hepatic Na(+)/bile acid cotransporters of the rabbit. I. Transport studies with membrane vesicles and cell lines expressing the cloned transporters.
Kramer W; Stengelin S; Baringhaus KH; Enhsen A; Heuer H; Becker W; Corsiero D; Girbig F; Noll R; Weyland C
J Lipid Res; 1999 Sep; 40(9):1604-17. PubMed ID: 10484607
[TBL] [Abstract][Full Text] [Related]
30. Human and rat precision-cut intestinal slices as ex vivo models to study bile acid uptake by the apical sodium-dependent bile acid transporter.
Li M; Vokral I; Evers B; de Graaf IAM; de Jager MH; Groothuis GMM
Eur J Pharm Sci; 2018 Aug; 121():65-73. PubMed ID: 29751102
[No Abstract] [Full Text] [Related]
31. Identification of a mutation in the ileal sodium-dependent bile acid transporter gene that abolishes transport activity.
Wong MH; Oelkers P; Dawson PA
J Biol Chem; 1995 Nov; 270(45):27228-34. PubMed ID: 7592981
[TBL] [Abstract][Full Text] [Related]
32. Expression and transport properties of the human ileal and renal sodium-dependent bile acid transporter.
Craddock AL; Love MW; Daniel RW; Kirby LC; Walters HC; Wong MH; Dawson PA
Am J Physiol; 1998 Jan; 274(1):G157-69. PubMed ID: 9458785
[TBL] [Abstract][Full Text] [Related]
33. Transmembrane domain VII of the human apical sodium-dependent bile acid transporter ASBT (SLC10A2) lines the substrate translocation pathway.
Hussainzada N; Banerjee A; Swaan PW
Mol Pharmacol; 2006 Nov; 70(5):1565-74. PubMed ID: 16899538
[TBL] [Abstract][Full Text] [Related]
34. Irinotecan-induced bile acid malabsorption is associated with down-regulation of ileal Asbt (Slc10a2) in mice.
Shi AX; Zhou Y; Zhang XY; Zhao YS; Qin HY; Wang YP; Wu XA
Eur J Pharm Sci; 2017 May; 102():220-229. PubMed ID: 28288854
[TBL] [Abstract][Full Text] [Related]
35. The solute carrier family SLC10: more than a family of bile acid transporters regarding function and phylogenetic relationships.
Geyer J; Wilke T; Petzinger E
Naunyn Schmiedebergs Arch Pharmacol; 2006 Mar; 372(6):413-31. PubMed ID: 16541252
[TBL] [Abstract][Full Text] [Related]
36. Conformational flexibility of helix VI is essential for substrate permeation of the human apical sodium-dependent bile acid transporter.
Hussainzada N; Khandewal A; Swaan PW
Mol Pharmacol; 2008 Feb; 73(2):305-13. PubMed ID: 17971420
[TBL] [Abstract][Full Text] [Related]
37. Apical sodium dependent bile acid transporter (ASBT, SLC10A2): a potential prodrug target.
Balakrishnan A; Polli JE
Mol Pharm; 2006; 3(3):223-30. PubMed ID: 16749855
[TBL] [Abstract][Full Text] [Related]
38. Homo- and hetero-dimeric architecture of the human liver Na⁺-dependent taurocholate co-transporting protein.
Bijsmans IT; Bouwmeester RA; Geyer J; Faber KN; van de Graaf SF
Biochem J; 2012 Feb; 441(3):1007-15. PubMed ID: 22029531
[TBL] [Abstract][Full Text] [Related]
39. Targeting the Four Pillars of Enterohepatic Bile Salt Cycling; Lessons From Genetics and Pharmacology.
Kunst RF; Verkade HJ; Oude Elferink RPJ; van de Graaf SFJ
Hepatology; 2021 Jun; 73(6):2577-2585. PubMed ID: 33222321
[TBL] [Abstract][Full Text] [Related]
40. Generation of a novel antibody probe to the apical sodium-dependent bile acid transporter that inhibits ileal bile acid absorption.
Montagnani M; Marangoni A; Roda A; Azzaroli F; Mazzella G; Roda E; Tsivian M; Neri F; Jovani M; Giandinoto M; Caponi A; Aldini R
Mol Pharm; 2009; 6(3):1012-8. PubMed ID: 19366255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
